CARDIFF ONCOLOGY INC (CRDF) Stock Fundamental Analysis

USA • Nasdaq • NASDAQ:CRDF • US14147L1089

1.6 USD
+0.12 (+8.11%)
At close: Feb 6, 2026
1.58 USD
-0.02 (-1.25%)
After Hours: 2/6/2026, 8:26:29 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

3

CRDF gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 524 industry peers in the Biotechnology industry. The financial health of CRDF is average, but there are quite some concerns on its profitability. CRDF is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

  • CRDF had negative earnings in the past year.
  • In the past year CRDF has reported a negative cash flow from operations.
  • In the past 5 years CRDF always reported negative net income.
  • CRDF had a negative operating cash flow in each of the past 5 years.
CRDF Yearly Net Income VS EBIT VS OCF VS FCFCRDF Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M -40M

1.2 Ratios

  • CRDF has a worse Return On Assets (-79.42%) than 66.41% of its industry peers.
  • The Return On Equity of CRDF (-103.82%) is comparable to the rest of the industry.
Industry RankSector Rank
ROA -79.42%
ROE -103.82%
ROIC N/A
ROA(3y)-43.63%
ROA(5y)-33.32%
ROE(3y)-50.23%
ROE(5y)-37.7%
ROIC(3y)N/A
ROIC(5y)N/A
CRDF Yearly ROA, ROE, ROICCRDF Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300

1.3 Margins

  • CRDF does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CRDF Yearly Profit, Operating, Gross MarginsCRDF Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -2K -4K -6K -8K -10K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. Health

2.1 Basic Checks

  • CRDF does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • CRDF has more shares outstanding than it did 1 year ago.
  • The number of shares outstanding for CRDF has been increased compared to 5 years ago.
  • CRDF has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
CRDF Yearly Shares OutstandingCRDF Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
CRDF Yearly Total Debt VS Total AssetsCRDF Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M

2.2 Solvency

  • Based on the Altman-Z score of -7.20, we must say that CRDF is in the distress zone and has some risk of bankruptcy.
  • Looking at the Altman-Z score, with a value of -7.20, CRDF is doing worse than 65.08% of the companies in the same industry.
  • There is no outstanding debt for CRDF. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -7.2
ROIC/WACCN/A
WACC8.85%
CRDF Yearly LT Debt VS Equity VS FCFCRDF Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M 100M

2.3 Liquidity

  • CRDF has a Current Ratio of 4.20. This indicates that CRDF is financially healthy and has no problem in meeting its short term obligations.
  • CRDF has a Current ratio (4.20) which is comparable to the rest of the industry.
  • A Quick Ratio of 4.20 indicates that CRDF has no problem at all paying its short term obligations.
  • The Quick ratio of CRDF (4.20) is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 4.2
Quick Ratio 4.2
CRDF Yearly Current Assets VS Current LiabilitesCRDF Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an nice 14.89% over the past year.
  • Looking at the last year, CRDF shows a very negative growth in Revenue. The Revenue has decreased by -27.29% in the last year.
  • CRDF shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 23.27% yearly.
EPS 1Y (TTM)14.89%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%32%
Revenue 1Y (TTM)-27.29%
Revenue growth 3Y23.8%
Revenue growth 5Y23.27%
Sales Q2Q%-27.27%

3.2 Future

  • Based on estimates for the next years, CRDF will show a decrease in Earnings Per Share. The EPS will decrease by -9.71% on average per year.
  • Based on estimates for the next years, CRDF will show a very strong growth in Revenue. The Revenue will grow by 178.11% on average per year.
EPS Next Y17.45%
EPS Next 2Y8.87%
EPS Next 3Y0.35%
EPS Next 5Y-9.71%
Revenue Next Year-24.43%
Revenue Next 2Y-22.54%
Revenue Next 3Y-32.52%
Revenue Next 5Y178.11%

3.3 Evolution

  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
CRDF Yearly Revenue VS EstimatesCRDF Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 200M 400M 600M 800M
CRDF Yearly EPS VS EstimatesCRDF Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 -20 -40 -60 -80

More info and screens

Find the best growth stocksShow best growing peers

0

4. Valuation

4.1 Price/Earnings Ratio

  • CRDF reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year CRDF is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CRDF Price Earnings VS Forward Price EarningsCRDF Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CRDF Per share dataCRDF EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y8.87%
EPS Next 3Y0.35%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • CRDF does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

CARDIFF ONCOLOGY INC

NASDAQ:CRDF (2/6/2026, 8:26:29 PM)

After market: 1.58 -0.02 (-1.25%)

1.6

+0.12 (+8.11%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-06
Earnings (Next)02-26
Inst Owners34.26%
Inst Owner Change-1.69%
Ins Owners2.4%
Ins Owner Change0%
Market Cap107.78M
Revenue(TTM)501.00K
Net Income(TTM)-50.65M
Analysts82.86
Price Target10.86 (578.75%)
Short Float %25.6%
Short Ratio12.13
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)5.8%
Min EPS beat(2)-6.95%
Max EPS beat(2)18.55%
EPS beat(4)2
Avg EPS beat(4)4.27%
Min EPS beat(4)-6.95%
Max EPS beat(4)18.55%
EPS beat(8)5
Avg EPS beat(8)7.75%
EPS beat(12)8
Avg EPS beat(12)8.32%
EPS beat(16)10
Avg EPS beat(16)5.93%
Revenue beat(2)2
Avg Revenue beat(2)11.19%
Min Revenue beat(2)10.73%
Max Revenue beat(2)11.65%
Revenue beat(4)4
Avg Revenue beat(4)22.6%
Min Revenue beat(4)10.73%
Max Revenue beat(4)57.2%
Revenue beat(8)8
Avg Revenue beat(8)117.23%
Revenue beat(12)12
Avg Revenue beat(12)112.21%
Revenue beat(16)16
Avg Revenue beat(16)103.59%
PT rev (1m)2.17%
PT rev (3m)2.17%
EPS NQ rev (1m)0.47%
EPS NQ rev (3m)12.81%
EPS NY rev (1m)0%
EPS NY rev (3m)7.96%
Revenue NQ rev (1m)-10%
Revenue NQ rev (3m)-15.56%
Revenue NY rev (1m)0%
Revenue NY rev (3m)6%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 215.12
P/FCF N/A
P/OCF N/A
P/B 2.21
P/tB 2.21
EV/EBITDA N/A
EPS(TTM)-0.8
EYN/A
EPS(NY)-0.77
Fwd EYN/A
FCF(TTM)-0.64
FCFYN/A
OCF(TTM)-0.64
OCFYN/A
SpS0.01
BVpS0.72
TBVpS0.72
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -79.42%
ROE -103.82%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-43.63%
ROA(5y)-33.32%
ROE(3y)-50.23%
ROE(5y)-37.7%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 12.02%
Cap/Sales 8.78%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.2
Quick Ratio 4.2
Altman-Z -7.2
F-Score2
WACC8.85%
ROIC/WACCN/A
Cap/Depr(3y)195.62%
Cap/Depr(5y)135.64%
Cap/Sales(3y)129.98%
Cap/Sales(5y)101.01%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)14.89%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%32%
EPS Next Y17.45%
EPS Next 2Y8.87%
EPS Next 3Y0.35%
EPS Next 5Y-9.71%
Revenue 1Y (TTM)-27.29%
Revenue growth 3Y23.8%
Revenue growth 5Y23.27%
Sales Q2Q%-27.27%
Revenue Next Year-24.43%
Revenue Next 2Y-22.54%
Revenue Next 3Y-32.52%
Revenue Next 5Y178.11%
EBIT growth 1Y-15.64%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-27.26%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-29.62%
OCF growth 3YN/A
OCF growth 5YN/A

CARDIFF ONCOLOGY INC / CRDF FAQ

What is the fundamental rating for CRDF stock?

ChartMill assigns a fundamental rating of 3 / 10 to CRDF.


What is the valuation status of CARDIFF ONCOLOGY INC (CRDF) stock?

ChartMill assigns a valuation rating of 0 / 10 to CARDIFF ONCOLOGY INC (CRDF). This can be considered as Overvalued.


How profitable is CARDIFF ONCOLOGY INC (CRDF) stock?

CARDIFF ONCOLOGY INC (CRDF) has a profitability rating of 0 / 10.


What is the expected EPS growth for CARDIFF ONCOLOGY INC (CRDF) stock?

The Earnings per Share (EPS) of CARDIFF ONCOLOGY INC (CRDF) is expected to grow by 17.45% in the next year.